[DOI] [PubMed] [Google Scholar] 77.Kannan L., Shaw P.A., Morley M.P., Brandimarto J., Fang J.C., Sweitzer N.K., Cappola T.P., Cappola A.R
Psychiatry , 51 (3), 241249
B) Immunohistochemistry with a monoclonal GPx4 antibody revealed low GPx4 expres- sion in KO testis compared to control tissue
Support Secondary Hormone Pathways (GIP, Amylin, Glucagon) GIP-like activity via insulin sensitizers (e.g., SLM+ ) Amylin via pramlintide (Symlin) or future CagriSema protocols Glucagon via activity, resistance training, or upcoming triple agonists Add agents that simulate or stimulate: 2
Because of their substantial benefit on some of the most highly prevalent disorders worldwide, GLP-1RAs have been hailed as game changers 8,9 and breakthrough drugs 10 , with an estimated market value of US$22.4 billion in 2022 and a compound annual growth rate of around 9.6% between 2023 and 2032 11
Neurophysiological analyses confirm that DSIP reduces nighttime awakenings and improves sleep quality without pharmacological burden
